Share on LinkedInShare on LinkedIn

ARTICLE · 04 SEPTEMBER 2018

Tribal Immunity Does Not Apply To IPR Proceedings

The US Court of Appeals for the Federal Circuit affirmed a Patent Trial and Appeal Board (PTAB) finding that tribal immunity does not apply to inter partes review (IPR) proceedings.

United StatesIntellectual Property

The US Court of Appeals for the Federal Circuit affirmed a Patent Trial and Appeal Board (PTAB) finding that tribal immunity does not apply to inter partes review (IPR) proceedings. Saint Regis Mohawk Tribe v. Mylan Pharmaceuticals, Inc., et al., Case Nos. 18-1638, -1639, -1640, -1641, -1642, -1643 (Fed. Cir. July 20, 2018) (Moore, J).

The appeal stems from a multi-front dispute between Allergan and various generic drug manufacturers regarding patents related to Allergan's Restasis product, a treatment for alleviating the symptoms of chronic dry eye. In 2015, Allergan sued the generic drug manufactures in the Eastern District of Texas, alleging infringement of its Restasis patents based on their filings of abbreviated new drug applications. In 2016, Mylan petitioned for IPR of Restasis patents, and the other generic drug manufacturers subsequently filed similar petitions. The PTAB instituted IPR and scheduled a consolidated oral hearing for September 2017.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from